- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Contrasting Timing of Virological Relapse after Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-negative Patients
Christoph Höner zu Siederdissen Aric Josun Hui Wattana Sukeepaisarnjaroen Pisit Tangkijvanich Wei Wen Su Gerardo Enrique Guillén Nieto Paul Gineste Josianne Nitcheu Sandrine Crabé Sandrine Stepien ... Show more
The Journal of Infectious Diseases, jiy350, https://doi.org/10.1093/infdis/jiy350
Published:
09 June 2018
Abstract
Stopping long-term nucleos(t)ide analogue therapy increases HBsAg loss rates in HBeAg-negative patients. Viral rebound may induce immune responses facilitating functional cure. We analyzed which factors are associated with timing of virological relapse in 220 Asian HBeAg-negative patients from the prospective ABX203 vaccine study. Unexpectedly, only the type of antiviral therapy was significantly associated with early virological relapse, defined as HBV DNA > 2,000 IU/ml until week 12 and occurred earlier in patients treated with tenofovir versus entecavir (median time 6 versus 24 weeks, p < 0.0001). This should be considered for future trials and monitoring of patients after treatment discontinuation.
Virological relapse, nucleos(t)ide discontinuation, tenofovir, entecavir, HBeAg negative hepatitis B virus infection
Issue Section:
Brief Report
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: [email protected].
|
|